SHANGHAI, 18. Juni 2024 /PRNewswire/ — MicroPort® CardioFlow Medtech Corporation (CardioFlow) (Aktiencode: 02160.HK) hat kürzlich bekannt gegeben, dass ihr selbst entwickeltes Gerät für die Transkatheter-Aortenklappenimplantation (TAVI) der zweiten Generation, die VitaFlow LibertyTM…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.